When mitoxantrone is activated by formaldehyde it can form adducts with DNA. These occur preferentially at CpG and CpA sequences and are enhanced 2-3-fold at methylated CpG sequences compared with non-methylated sites. We sought to understand the molecular factors involved in enhanced adduct formation at these methylated sites. This required, first, clarification of factors that contributed to the formation of adducts at CpG sites. For this purpose mass spectrometry of an oligonucleotide duplex (containing a single CpG adduct site) was used to confirm the presence of an additional carbon atom (derived from formaldehyde) on the drug-DNA complex. The effect of 3-flanking sequences was revealed by electrophoretic analysis of oligonucleotidedrug adducts, and the preferred adduct-forming site was identified as 5-CGG-3. Radiolabeled studies of drug-DNA adducts confirmed that the site of attachment involved the exocyclic amino of guanine. Molecular modeling analysis of the relative stability of the intercalated form of mitoxantrone was consistent with observed adduct-forming potential of CG sites with varying flanking sequences. The known preference for adduct formation at methylated CG sites was confirmed by energetics calculations and shown to be due to a shift of equilibrium of the intercalated form of the drug from the major groove (at CG sites) to the minor groove (at methylated CG sites). This increases the relative amount of drug that is located adjacent to the N-2 exocyclic amino of guanine in the minor groove, where covalent linkage is facilitated. These results account for the enhanced covalent binding of mitoxantrone to methylated CG sequences and provide a molecular model of the interactions.
Mitoxantrone is a classic intercalating agent that accumulates in the nucleus where it functions as a topoisomerase II poison, and there is good evidence that the impaired topoisomerase II (i.e. stabilized DNA-topoisomerase II-cleavable complex) contributes to the cytotoxic effect of mitoxantrone (4) . However, in addition to this mechanism it has also been demonstrated that the oxidation products of mitoxantrone (catalyzed by horseradish peroxidase) form a covalent complex with DNA in vitro (5) , and similar drug-DNA adducts were subsequently also detected when mitoxantrone was oxidized in vitro by the human enzyme myeloperoxidase (6) . The detection of drug-DNA adducts in mitoxantrone-treated promyelocytic HL-60 cells (which contain myeloperoxidase) (7) and in other tumor cells (8) subsequently provided direct support for the notion that mitoxantrone-DNA adducts may contribute to the mechanism of action of mitoxantrone.
Over recent years it has become clear that doxorubicin can be activated by formaldehyde in vitro and the activated species formed adducts with DNA (9 -11) . The structure of doxorubicin-DNA adducts has been rigorously defined by mass spectrometry, two-dimensional NMR, and x-ray diffraction (for review, see Ref. 12) , and low levels of these adducts have been detected in MCF-7 tumor cells in culture (13) . The combination of doxorubicin with formaldehyde-releasing prodrugs yields dramatically enhanced levels of doxorubicin-DNA adducts and results in a synergistic increase of cytotoxicity (14) .
The structural and potential mechanistic similarities between mitoxantrone and doxorubicin suggested that mitoxantrone may also be activated by formaldehyde, and this was subsequently confirmed in vitro using an electrophoretic DNA cross-linking assay (15) . This assay also revealed that the mitoxantrone-DNA adducts were labile, similar to that observed with doxorubicin-DNA adducts (16) , and suggested a likely structure (15) for these adducts (Fig. 1B ). An in vitro transcription assay revealed that the adducts formed specifically at CpA and CpG, with greater stability (half-life of 3.0 -5.3 h) at CpG sites (17) , in contrast to the well documented GpC sequence specificity of anthracycline-DNA adducts (11, 12) .
The knowledge that mitoxantrone formed adducts preferentially at CpG sequences together with the fact that the majority of CpG dinucleotides in cells are methylated (18) prompted an investigation into the effect of mitoxantrone-DNA adduct formation at methylated CpG sites. In vitro transcription analysis revealed that adduct levels at 5-methyl-CG sites were enhanced 2-3-fold compared with non-methylated CG sequences (19) . Methylation of cytosine at single CpG sites on oligonucleotides also revealed that adduct levels were enhanced 3-fold by the presence of the methylated cytosine (19) .
Recently, we have shown that in tumor cells in culture the activity of mitoxantrone depends on the methylation status of the cell (20) . Mitoxantrone-DNA adduct levels decreased when breast cancer cells were pretreated with the DNA de-methylating agent 5-aza-2-deoxycytidine, 1 and DK08 cells in which the DNA methyltransferase activity had been knocked out (resulting in a 50% decrease of methylation levels compared with the parental HCT116 cells) were also less sensitive to mitoxantrone (20) . Both of these results are consistent with the view that some of the mechanism of action of mitoxantrone may be due to formaldehyde-mediated formation of mitoxantrone-DNA adducts at methylated CpG sequences.
Because the activity of mitoxantrone depends on the methylation status of CpG sequences together with the known critical role of CpG islands and hypermethylation of these regions in regulating gene expression (21) (22) (23) , we sought to understand how cytosine methylation at these sites affected mitoxantrone-DNA adduct formation. We show here the effect of DNA flanking sequences on adduct-forming capacity in model oligonucleotides that contain only a single CpG site, the effect of methylation at these sites, and also molecular modeling studies of mitoxantrone-DNA adducts, which account for the critical role of cytosine methylation on adduct formation.
EXPERIMENTAL PROCEDURES

Materials
Mitoxantrone was kindly provided by Lederle Laboratories (Pearl River, NY). The drug stock solution was prepared by dissolving in Milli-Q water (Millipore, MA) to a final concentration of 2 mM and stored at Ϫ20°C. All oligonucleotides were obtained from Gene Works. Deoxynucleotides (dNTPs), poly(dI-dC) and poly(dG-dC) were purchased from Amersham Biosciences. DyNAzyme DNA polymerase was from Finnzymes, acrylamide and urea were from ICN Biomedicals Inc., bisacrylamide and ammonium persulfate were from Bio-Rad, formamide and 5-aza-2-deoxycytidine were from Sigma-Aldrich, glycogen and 7-deaza-2Ј-dGTP were from Roche Applied Science, phenol was from Invitrogen, formaldehyde was from BDH and, Ready Safe liquid scintillation mixture was from Beckman-Coulter. Micro Bio-Spin P6 columns were from Bio-Rad, and Nensorb™ 20 columns were from PerkinElmer Life Sciences.
Methods
Preparation of Oligonucleotides-All 20-mer oligonucleotides (see Table I ) were purified electrophoretically using a 19% denaturing acrylamide gel preheated to 50°C for 2 h at 2100 V. The DNA was visualized by UV shadowing on a TLC plate with fluorescein indicator and retrieved from the acrylamide matrix by incubation in water at 37°C overnight. Samples were subsequently concentrated using Centricon 3 columns. The relevant oligonucleotide (100 pmol) was end-labeled using T4 polynucleotide kinase and [␥-32 P]ATP, and unincorporated label was removed by passing the sample through a micro Bio-Spin 6 chromatography column. Complementary oligonucleotides were annealed by heating at 70°C for 5 min followed by gradual cooling to room temperature and storage at Ϫ20°C.
Mitoxantrone-Oligonucleotide Adduct Formation-Radiolabeled oligonucleotide duplexes (25 M bp) were incubated with 40 M mitoxantrone and 0 -50 mM formaldehyde at room temperature for 5.5 h. Samples were subsequently subjected to overnight electrophoresis at 4°C on a 19% denaturing acrylamide gel (7 M urea, 19:1 acrylamide: bisacrylamide) at 600 V. Labeled DNA was then visualized by PhosphorImager analysis using a Model 400B PhosphorImager, and bands were quantitated using ImageQuant software (Molecular Dynamics, CA).
Drug-Oligonucleotide Stability-Drug-reacted oligonucleotides were passed through a gel exclusion column (Bio-Rad Micro Bio-Spin P-6 chromatography columns) to remove non-reacted drug, incubated at 37°C for up to 120 min, then subjected to overnight electrophoresis at 4°C on a 19% denaturing polyacrylamide gel (7 M urea, 19:1 acrylamide:bisacrylamide) at 600 V. The gel was then vacuum-dried on a Bio-Rad Model 583 gel drier and exposed to a phosphor screen overnight. The gel was analyzed, and the bands were quantitated as described above.
Mass Spectrometry-A 12-mer self-complementary oligonucleotide (100 M bp) containing a single CG binding site (5Ј-TTTAACGTTAAA-3Ј) was reacted with 40 M mitoxantrone and 10 mM formaldehyde in a final volume of 50 l. The samples were desalted four times into 10 mM ammonium acetate by gel filtration (Bio-Rad Micro Bio-Spin P-6) to reduce contamination of sodium. Electrospray ionization mass spectrometry was then carried out in the negative ion mode on a PerkinElmer SCIEX API-300 triple quadrupole mass spectrometer fitted with a micro-ion spray ion source (flow rate 0.2 l/min).
Preparation of N-7-modified DNA-Fragments of 572-bp DNA containing either guanine or 7-deaza-2Ј-deoxyguanine were generated by PCR. Approximately 160 ng of the plasmid pCCl (24) amplify the 572-bp fragment in 1 ϫ DyNAzyme buffer containing 18.8 g/ml each of two oligonucleotide primers (5Ј-AGAATACAAGCTT-GGGCTGC and 5Ј-AATACGCAAACCGCCTCTC-3Ј), 200 M each dATP, dCTP, dTTP, and either dGTP or 7-deaza-2Ј-dGTP, 9.4 units/ml DyNAzyme Taq polymerase, and 1.5 mM MgCl 2 . PCR was performed in a PerkinElmer GeneAMP PCR System 2400 using the program 94°C for 1 min, 62°C for 1 min, and 72°C for 75 s for 30 cycles. The two amplified 572-bp fragments were excised from a 0.8% agarose gel, subjected to electroelution, purified by phenol/chloroform extraction and ethanol precipitation, and then resuspended in Tris-EDTA buffer. The concentration of the 572-bp fragments was determined spectrophotometrically using E ϭ 13,200 M Ϫ1 cm Ϫ1 at 260 nm.
Formation of Mitoxantrone-DNA Adducts with N-2 and N-7-modified
DNA-The 572-bp fragments (25 M bp), containing either guanine or 7-deaza-2Ј-deoxyguanine, were treated with 20 M [
14 C]mitoxantrone and 3 mM formaldehyde for 2 h at 37°C to generate mitoxantrone-DNA adducts. The reaction was terminated and the DNA was purified using a phenol/chloroform extraction followed by an ethanol precipitation. DNA was then resuspended in 75 l of Tris-EDTA buffer. Scintillation fluid (1 ml) was added to each sample, and the [ 14 C]mitoxantrone-DNA adducts were quantitated by scintillation analysis using a Wallac 1410 liquid scintillation counter. For determination of the role of the N-2 exocyclic amino group in adduct formation, the synthetic polynucleotides poly(dI-dC) and poly(dG-dC) were dissolved in Tris-EDTA buffer (concentrations were determined spectrophotometrically using E ϭ 6900 M Ϫ1 cm Ϫ1 at 251 nm and E ϭ 8400 M Ϫ1 cm Ϫ1 at 254 nm, respectively). The synthetic alternating co-polymers were then reacted with [ 14 C]mitoxantrone, and adducts levels were determined as described above.
Molecular Modeling-Energy calculations were performed using Sybyl (Tripos). MMFF94 Forcefield and charges were used in all energy minimization, energetics, and optimizations (25, 26) , whereas Tripos Forcefields were used in all energy calculations since it enabled bonded molecules to be split and their energies calculated independ-
TABLE I Effect of 3Ј-flanking sequence
The extent of cross-linking and half-life of the adduct together with calculated values for the relative energy of formation at 5Ј-CG-3Ј central sites for both intercalated and covalently bound form of mitoxantrone with 20-mer AT 4 A 3 N 4 T 3 A 4 T oligonucleotide duplexes are shown. The final column shows only the H-bond contribution to the intercalated form of the drug. The central 4-bp N 4 element, which contains the 5Ј-CG-3Ј mitoxantrone binding sequence (or alternate control sequences), has been separated from the remainder of the sequence to highlight this region. For clarity, only one strand of each duplex is shown. Errors for the half-life of decay of mitoxantrone-oligonucleotide adducts reflect the S.E. of fit of the decay (average of Ϯ 12%), consistent with replicates of individual data points (n ϭ 2) where the average error was Ϯ 10%. ently of each other. Energy calculations were based on the relationship E interaction ϭ E total ϩ E fragments , in which the extent of the interaction energy can be calculated by subtracting the energies of the individual fragments (DNA and mitoxantrone) from the energy of the whole system. Each energy term is composed of two main components (electrostatic interactions and Van der Waals forces), with E ϭ E electrostatic ϩ E Van der Waals . All energies are relative and cannot be used to determine absolute reactivity. The DNA 20-mer fragment (5Ј-ATTTTAAAACGN-TTTAAAAT-3Ј) was constructed using the Sybyl Biopolymer Module, and the canonical B-DNA structure was used for all calculations.
RESULTS
Effect of Flanking Sequences on Adduct Formation and Stability-
We have recently used an in vitro transcription assay to identify the sequence specificity of mitoxantrone-DNA adducts, and all high occupancy sites were observed only at 5Ј-CG and 5Ј-CA sequences, with the highest occupancy occurring at 5Ј-CG sequences (17) . Although some 19 adduct sites were identified in the 120 bp probed in that assay, it was not possible to identify preferred flanking sequences. In the present study we have used 20-mer oligonucleotide duplexes that contained a single, central mitoxantrone 5Ј-CG adduct site to assess the effect of the 3Ј-flanking sequence. Each of the oligonucleotides was reacted overnight with 40 M mitoxantrone and increasing concentrations of formaldehyde, and the extent of adduct formation was assessed by an electrophoretic DNA cross-linking 32 P end-labeled 20-mer oligonucleotides (25 M bp) were reacted overnight with 40 M mitoxantrone and 50 mM formaldehyde at room temperature, then purified using a Bio-Spin 6 gel exclusion column. At various times after purification (0 -120 min) they were subjected to electrophoresis, and relative adduct levels were determined as the extent of residual cross-linked DNA as outlined in Fig. 2 . B, the time-dependent loss of adduct levels is shown for each of the four 20-mer oligonucleotide duplex sequences examined.
FIG. 4. Effect of guanine modifications on mitoxantrone-DNA adduct formation. [
14 C]Mitoxantrone (20 M) was reacted with 25 M DNA bp for 2 h at 37°C in the presence of 3 mM formaldehyde. After phenol/chloroform extraction of the DNA, 14 C-labeled DNA adducts were quantitated by scintillation counting and represented as adducts/10 kilobases (kb). The DNA samples were a normal DNA fragment (denoted 572 bp), the same 572 bp fragment containing 7-deazaguanine instead of guanine (Deaza 572 bp), poly (dG-dC), and poly (dI-dC). A control reaction was carried out in the absence of formaldehyde with the normal 572-bp fragment.
assay. Fig. 2 shows that the central 4-bp sequences with the greatest adduct-forming capacity were 5Ј-ACGG and 5Ј-ACGC (i.e. G and C to the 3Ј end of the CG adduct site) and that the extent of adduct formation was ACGG Ͼ ACGC Ͼ ACGA Ͼ ACAG Ͼ ACGT. Control sequences were also utilized in which the central site did not contain a known mitoxantrone adductforming sequence (i.e. 5Ј-GC and 5Ј-AT), and as expected, no adducts were detected with these sequences (Table I) , consistent with the previously documented requirement for 5Ј-CG and 5Ј-CA sequences for mitoxantrone-DNA adduct formation (17) . Because adducts stabilize the duplex to the extent that they withstand normal thermal denaturation conditions, the extent of duplex structures remaining after denaturation is a direct measure of the extent of adduct formation on that DNA sequence (15) .
Once the adducts had been formed their stability was assessed by removing the reactants (mitoxantrone and formaldehyde) from the reaction mixture by gel exclusion chromatography and monitoring the residual cross-linked complex as a function of time (Fig. 3) . The two sequences that exhibited the greatest adduct stability (longest half-life) were those that contained either G or C located 3Ј to the central 5Ј-CG adduct site, consistent with the observed preference for adduct formation at 5Ј-CG(C/G)-3Ј sequences (Table I) . It should be noted that the stability of mitoxantrone-oligonucleotide adducts is considerably less than reported previously using an in vitro transcription assay (17) , and this difference is thought to reflect the greater structural flexibility of the 20-bp oligonucleotides (compared with the 512-bp DNA fragment used in the in vitro transcription assay) as well as the effect of RNA polymerase on the drug dissociation process.
Site of Attachment of Mitoxantrone to DNA-Although a tentative structure has been proposed for mitoxantrone-DNA adducts (14) based on the analogy with doxorubicin-DNA adducts (9 -12), there is no direct experimental evidence to support this model. To establish if the mitoxantrone-DNA link involved either the well documented reactive and accessible N-7 of guanine or the exocyclic N-2 amino of guanine, adducts were formed with a 572-bp PCR-amplified fragment of DNA that contained either guanine at all relevant positions or deaza-guanine (i.e. C-7 instead of N-7) at all positions as well as with poly(dG-dC) (where G contains the N-2 exocyclic amino group) and poly(dI-dC) (where I lacks the exocyclic N-2 amino group). The loss of the N-7 moiety reduced the adduct level somewhat, whereas removal of the N-2 amino group completely abolished adduct formation (Fig. 4) . This result, therefore, establishes the absolute requirement for the N-2 amino of guanine for mitoxantrone-DNA adduct formation. As a control, reactions were also carried out in the absence of formaldehyde, and as expected, only background levels of adducts were detected (Fig. 4) .
Mass Spectrometry of the Mitoxantrone-Oligonucleotide Adduct-The proposed structure of mitoxantrone-DNA adducts (14) involves a N-C-N aminal linkage where the central carbon of this linkage is derived from formaldehyde. It is assumed that formaldehyde reacts with a secondary nitrogen on the side chain of mitoxantrone to form a Schiff base and that this activated drug then reacts with the N-2 exocyclic amino of guanine to form an adduct with DNA. Although both side chains could potentially be activated by this process, there is no evidence to date that both side chains can simultaneously form an aminal linkage to DNA to form a substantially more stable interstrand cross-link. If this is the case and the mitoxantrone-DNA adduct is linked to only one strand of DNA, the adduct would yield a molecular weight consisting of one strand of the oligonucleotide plus mitoxantrone and one carbon (i.e. CH 2 from formaldehyde, less 2H atoms, which are lost accompanying the formation of the aminal linkage). To establish if this was indeed the case, a 12-mer oligonucleotide duplex with only one central 5Ј-CG adduct-forming site (5Ј-TTTAACGTTAAA-3Ј) was reacted with mitoxantrone and formaldehyde, extensively desalted to reduce the sodium ion level to minimal levels (to assist ionization of the oligonucleotide), and subjected to negative mode microelectrospray mass analysis. Molecular masses observed were 4088.0 Ϯ 0.7 and 4100.4 Ϯ 0.7, consistent with the calculated mass of 4088.4 for the non-covalent oligonucleotide-mitoxantrone complex and 4100.4 for the covalent oligonucleotide-methylene-mitoxantrone complex (Fig. 5) , where the additional 12 Da is due to the methylene carbon derived from formaldehyde.
Energetics of Cytosine Methylation-We have previously shown that when mitoxantrone is reacted with 20-mer oligonucleotide duplexes in the presence of formaldehyde up to 3-fold more adducts were formed with the oligonucleotide that contained a central methylated cytosine (i.e. 5Ј-A me CGG-3Ј, me CG is 5-methyl-CG) sequence compared with the non-methylated sequence (i.e. 5Ј-ACGG-3Ј) and that adducts formed at the methylated site were also more stable than at the nonmethylated sequence (Ref. 19 ; summarized in Table II ). To establish how cytosine methylation caused such a dramatic enhancement of adduct formation together with a corresponding increase of biological activity (19, 20) we determined the relative free energy of binding of mitoxantrone to each se- quence (with intercalation of the drug chromophore between the C and G residues) with the drug intercalated in either the major or minor groove, and these energies are summarized in Table II . Binding via the major groove was much more favorable than the minor groove for the non-methylated sequence, and this is consistent with previous NMR studies which revealed that the drug side chains were located in the major groove (29) . However, there was little groove preference for binding to the methylated sequence. The reason that the binding energies for intercalation via the minor groove is independent of whether the cytosine is methylated or not is because the methyl group on cytosine is at the 5 position; since this projects into the major groove it does not interfere with access to the minor groove (Fig. 1C) . The effect of methylation then is to shift the equilibrium of bound drug from the major groove in the non-methylated sequence to the minor groove for methylated sequences. Because the N-2 exocyclic amino group is in the minor groove, this facilitates more adduct formation when the CG site is methylated because more drug is now intercalated at that site and in close proximity to the amino of guanine.
Energetics of the Intercalation Site at CG SequencesWhereas it was clear from in vitro transcription studies that RNA polymerase was blocked at 5Ј-CG sequences, the assay did not reveal the exact location of the drug chromophore (i.e. whether it was between the C and G or to the 5Ј or 3Ј side of the central CG dinucleotide). To answer this question the binding energies were calculated for intercalation at each of these sites, and the preferred site was clearly between the two central CG bp (Table III) . We then attempted to resolve whether the drug bound covalently to the G of the central CG dinucleotide or to the G on the opposite strand. However, there was insufficient difference of relative binding energy to resolve this issue, and at this stage we conclude that covalent attachment to either guanine residue is equally likely.
Energetics of the Effect of Flanking Sequences-The extent of adduct formation with different oligonucleotide sequences revealed that maximal adduct levels were detected when the nucleotide 3Ј to the central CG dinucleotide was either C or G (Table I) . Although total binding energies were unable to discriminate between the different 3Ј-flanking nucleotides (irrespective of whether the drug was intercalated or bound covalently via the minor groove), the H-bond contributions between the central 4-bp region of the oligonucleotide duplex and a single side chain of mitoxantrone provided good insight into the relative affinity of mitoxantrone for each sequence. This analysis revealed a pronounced preference for the two sequences that exhibited most adduct formation (i.e. 5Ј-CG flanked on the 3Ј end by either G or C), and the H-bond contributions were fully consistent with the extent of adduct formation for the four oligonucleotide sequences studied experimentally (Table I ). The specific groups involved in the Hbonding as well as the inter-atomic distances are shown in Fig.  6 for all four sequences examined.
Molecular Modeling of Intercalated and Covalent Mitoxantrone-DNA Complexes-With the insight gained of molecular contributions to mitoxantrone-DNA adduct formation (i.e. drug chromophore intercalated between the central C and G of the CG dinucleotide; binding via the minor groove; 5Ј-ACGG-3Ј as a preferred sequence) an energy-minimized structure was constructed for both the intercalated and covalently bound forms of the complex (Fig. 7) . The specific groups that provide H-bonding contributions to this energyminimized structure are shown in Fig. 8 both for the intercalated and covalently bound form of mitoxantrone. For the intercalated form the side chains bind essentially symmetrically in the minor groove but become distinctly nonsymmetric when the drug is covalently attached to DNA (Fig.  7) . This is due to the N-C-N aminal linkage (where the C from formaldehyde is shown in gold), which brings one side chain in closer to the guanine residue to which it is attached, but has the opposite effect on the other side chain, moving it further away from the guanine on the opposite strand. This conformational effect, therefore, effectively prevents the formation of a second aminal linkage to DNA, and this is consistent with the fact that formaldehyde-activated mitoxantrone does not appear to be able to form a conventional interstrand cross-link (15) .
Relationship of Adduct Sites to Topoisomerase II Cleavage Sites-That a preferred site for mitoxantrone-DNA adduct formation at CGG sequences corresponds to a preferred site for mitoxantrone-induced enhancement of topoisomerase II cleavage (27) raised the possibility that topoisomerase II cleavage by mitoxantrone might be affected by adduct formation. To address this question we used the cleavage assay of Gupta et al. (28) , in which an end-labeled fragment of DNA (512 bp) was cleaved with topoisomerase II (Topogen). However, the extent of cleavage was not significantly affected by whether mitoxantrone was present as the free drug or activated by 2 mM formaldehyde to form mitoxantrone-DNA adducts. A topoisomerase II-mediated relaxation assay (25) was also used to address this question, and again, no major effect on DNA relaxation was observed accompanying the formation of mitoxantrone-DNA adducts. It, therefore, appears that adduct formation at CGG sites does not dramatically affect topoisomerase II-mediated responses at these sites.
DISCUSSION
Stereochemical Model of Mitoxantrone-DNA Adducts-The energy-minimized model of mitoxantrone-DNA adducts (Fig. 7) is consistent with all present and previous experimental in vitro and cellular observations as follows. 1) Adduct levels increase with formaldehyde. 2) Adducts are linked to the exocyclic N-2 amino of guanine. 3) All adduct sites involve guanine. 4) The adducts are labile, consistent with the known lability of aminal linkages. 5) Mitoxantrone-DNA adducts are less stable than the analogous doxorubicin-DNA adducts, which involve Schiff base formation with the primary amino of doxorubicin rather than a secondary amino group in the side chain of mitoxantrone. 6) Mass spectrometry data indicates covalent bonding to only one strand of DNA. 7) Mass spectrometry confirmed the addition of only one carbon group to the adduct, consistent with the reaction of formaldehyde with mitoxantrone by Schiff base chemistry and the formation of an aminal linkage.
The energy calculations also indicated that the drug chromophore would be located between the C and G of the preferred adduct, forming 5Ј-CG dinucleotide, and that mitoxantrone could be linked with similar probability to either guanine residue abutting the intercalation site. This phenomenon also explains why high adduct levels are also observed at 5Ј-CA sequences, because mitoxantrone is able to bind covalently to the guanine adjacent to the intercalation site but, in this case, on the opposite DNA strand.
Although energy calculations of the total drug-DNA complex were not sufficiently sensitive to be able to discriminate between the different flanking sequences for preferred adduct forming potential, a critical subset of the drug-DNA interactions was exceedingly informative. When only H-bond contributions between the side chain of mitoxantrone and DNA were considered, there was an excellent correlation between the stabilization energy from this source and the extent of adduct formation (Table I) . It, therefore, appears likely that the major determinant of preferred adduct-forming sequences is due to the extent of H-bonding between mitoxantrone and the 3 bp on either side of the intercalation site.
Effect of Cytosine Methylation-The most fundamental finding of the molecular modeling analysis of mitoxantrone-DNA interactions was that methylation of cytosine shifted the intercalated drug equilibrium from predominately in the major groove to an increased probability of binding via the minor groove. This occurs because 5-methylation of cytosine results in projection of the methyl group into the major groove, thereby diminishing access of mitoxantrone to the 5Ј-CG intercalation site, whereas access to the same intercalation site is totally unaffected by the cytosine methylation. Once more drug is intercalated via the minor groove, it is then positioned immediately adjacent to a potentially reactive N-2 exocyclic amino of guanine (i.e. the G of the 5Ј-CG intercalation site). If formaldehyde is also present, then it is reasonable to suggest that rapid intercalation kinetics ensures that some of the intercalated drug will react with formaldehyde to form a Schiff base and then react further with the adjacent N-2 amino of guanine to form the N-C-N aminal linkage. However, it should be noted that the order of formation of the aminal linkage is not known, and it is also conceivable that a small percentage of N-2 amino groups of guanine may be first activated by formaldehyde and that the second step involves coupling between the intercalated drug and the Schiff base of guanine.
Biological Implications-There are now many questions and issues to be addressed with respect to the possible cellular responses to mitoxantrone-DNA adducts and to the further implications of these adducts in cellular systems. Although it is now clear that mitoxantrone adduct formation at CpG sites is enhanced 2-3-fold in vitro when the cytosine is methylated (19) , it has not yet been confirmed that adducts do in fact form preferentially at 5-methyl-CG sites in CpG islands, which are typically associated with promoter regions in mammalian cells (21) (22) (23) , and we are presently examining this issue.
A further complex issue to be addressed is the relationship between mitoxantrone and topoisomerase II and how this might be affected by mitoxantrone adduct formation at 5Ј-CG and 5Ј-methyl-CG sites. Although mitoxantrone is a well known topoisomerase II poison, it is not yet clear how this cellular response will be affected by increasing levels of adduct formation at these sites. A fundamental question to be addressed is whether the adducts supplement the topoisomerase II response or whether they sequester drug away from topoisomerase II to form more lethal DNA lesions, thus potentially accounting for the observed increased cytotoxicity of mitoxantrone when activated by formaldehyde-releasing prodrugs.
